Economic impact of donor platelet count and platelet yield in apheresis products: Relevance for emerging issues in platelet transfusion therapy

Vox Sanguinis

Volumn 76, Issue 1, 1999, Pages 43-49

  Goodnough, Lawrence Tim ^a,b   Ali, Suhail ^a   Despotis, George ^a   Dynis, Marian ^a   DiPersio, John F ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD DONOR; CELL SEPARATION; CONTROLLED STUDY; ECONOMIC ASPECT; EQUIPMENT; FEMALE; HEALTH CARE COST; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS;

ADULT; AGE FACTORS; BLOOD BANKS; BLOOD DONORS; BLOOD PLATELETS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MISSOURI; MULTIVARIATE ANALYSIS; PLATELET COUNT; PLATELET TRANSFUSION; PLATELETPHERESIS; SEX FACTORS; STATISTICAL DISTRIBUTIONS;

EID: 0032898716     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000031018     Document Type: Article

References (23)

1. Wallace EL, Churchill WH, Surgenor DM, et al: Collection and transfusion of blood and blood components in the United States. 1992. Transfusion 1995;35:802-812.
2. Goodnough LT, Bodner MS, Martin JW: Blood transfusion and blood conservation: Cost and utilization issues. Am J Med Qual 1994;9:172-183.
3. Bensinger WI, Weaver CH, Appelbaum FR, et al: Transplantation of allogeneic peripheral blood system cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 1995;85:1655-1659.
4. York A, Clift RA, Sanders JE, Buckner CD: Recombinant human erythropoietin administration to normal marrow donors. Bone Marrow Transplant 1992;10:415-417.
5. Bensinger WI, Price TH, Dale DC, et al: The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81:1883-1888.
6. Kuter D, Miyazaki H, Kato T: The purification of thrombopoietin from thrombocytopenic plasma, in Kuler D, Hunt P, Sheridan WP, Zucker-Franklin D, (eds):Thrombopoiesis and Thromhopoietins: Molecular, Cellular, Preclinical, and Clinical Biology, Totowa, Humana Press, 1996, pp 143-164.
7. Eaton D: The purification and cloning of human thrombopoietin, in Kuter D, Hunt P, Sheridan WP, Zucker-Franklin D (eds): Thrombopoiesis and Thrombopietins: Molecular, Cellular, Preclinical, and Clinical Biology. Totowa, Humana Press, 1996, pp 135-141.
8. O'Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, Hopkins W, Cohen B, O'Byrne J, Green MD, Fox RM, Berndt MC, Begley CG: Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996;88: 3288-3298.
9. O'Malley CJ, Rasko JEJ, Basser RL, et al: Administration pegylated recombinant human magakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996;88:3288-3298.
10. TRAP Trial Study Group: Leukocyte-reduction and UV-B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337: 1861-1869.
11. Kruskall MS: The perils of platelet transfusions. N Engl J Med 1997;337:1914-1915.
12. Rosario MLU, Kao KJ: Determination of the rate of reduction in platelet counts in recipients of hematopoietic stem cell and progenitor cell transplant: Clinical implication for platelet transfusion therapy. Transfusion 1997;37: 1163-1168.
13. Rebulla P, Finazzi G, Marangoni F, et al: The threshold for prophylactic platelet transfusion in adults with acute myeloid leukemia. N Engl J Med 1997;337:1870-1875.
14. Burgstaler EA, Pineda AA, Brecher MA: Platelet pheresis: Comparison of platelet yields, processing time, and white cell content with two apheresis systems. Transfusion 1993;33:393-398.
15. Hester JP, Ventura GJ: Modeling of platelet concentrate yield in continuous-flow cell separation devices. J Clin Apheresis 1988;4:188-193.
16. Fanucchi M, Glaspy J, Crawford J, et al: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404-409.
17. Basser RL, Rasko J, Clarke K, et al: Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997;89:3118-3128.
18. Tomita D, Petrarla M, Pane T, Olson K, Roskos L, Cheung E: Effect of a single dose of pegylated human recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet counts: Implications for platelet apheresis. Transfusion 1997;37:25.
19. Goodnough LT, DiPersio J, McCullough J. Peterson R, Armstrong S, Menchaca D, Tomita D, Romo J, Kuter D: Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases platelet (PLT) count (CT) and apheresis yields of normal platelet donors: Initial results. Transfusion 1997;37:67S.
20. Kuter D, McCullough J, Romo J, DiPersio J, Peterson R, Armstrong S, Menchacha D, Tomita D, Goodnough LT: Treatment of platelet donors with pegylated recombinant human megakaryocyte growth and development factor increases circulating platelet counts and platelet apheresis yields and increases platelet increments in recipients of platelet transfusion. Blood 1997;50:579a.
21. Villeval JL, Solar KC, Tulliez M, et al: High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997;90:4369-4383.
22. Norol F, Bierling P, Roudot-Thoraval F, Le Cœur FF, Rieux C, Lavaux A, Kuentz M, Duedari N: Platelet transfusion: A dose-response study. Blood 1998;92:1448-1453.
23. Hersh JK, Hom EG, Brecher ME: Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronic platelet transfusion dependent patient. Transfusion 1998;38:637-644.